[1]闫竹梅,王 兰.沙库巴曲缬沙坦钠治疗蒽环类药物所致心肌损害临床疗效观察[J].陕西医学杂志,2021,50(6):726-730.[doi:DOI:10.3969/j.issn.1000-7377.2021.06.022]
　YAN Zhumei,WANG Lan.Clinical efficacy of sacubitril valsartan sodium in treatment of myocardial damage induced by anthracycline[J].,2021,50(6):726-730.[doi:DOI:10.3969/j.issn.1000-7377.2021.06.022]
点击复制

沙库巴曲缬沙坦钠治疗蒽环类药物所致心肌损害临床疗效观察
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
50
期数:
2021年6期
页码:
726-730
栏目:
药物与临床
出版日期:
2021-06-05

文章信息/Info

Title:
Clinical efficacy of sacubitril valsartan sodium in treatment of myocardial damage induced by anthracycline
作者:
闫竹梅1; 王 兰2
(1.榆林市中医医院老年病科,陕西 榆林 719000; 2.西安市第一医院心内科,陕西 西安 710002)
Author(s):
YAN Zhumei; WANG Lan
(Department of Geriatrics,Yulin Hospital of Traditional Chinese Medicine,Yulin 719000,China)
关键词:
沙库巴曲缬沙坦钠;  蒽环类药物;  心脏毒性;  抗心肌肌钙蛋白I自身抗体;  可溶性信号素4D;  miR-34a-5p
Keywords:
Sacubitril valsartan sodium;  Anthracycline;  Cardiotoxicity;  CTnIAAb;  SSema4D;  MiR-34a-5p
分类号:
R 542.2
DOI:
DOI:10.3969/j.issn.1000-7377.2021.06.022
文献标志码:
A
摘要:
目的:观察沙库巴曲缬沙坦钠治疗蒽环类药物所致心肌损害的临床疗效。方法:选取应用包含阿奇霉素化疗方案治疗后有心肌损害表现的患者70例作为研究对象,随机分为观察组和对照组,每组35例。对照组进行纠正电解质紊乱、去除诱因等常规治疗。观察组在对照组的基础上给予沙库巴曲缬沙坦钠片口服,持续治疗12周。比较两组患者治疗总有效率,治疗前后堪萨斯城心肌病患者生活质量量表(KCCQ)评分、左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、心肌校正的背向散射积分均值(IBS%)、背向散射积分周期变异率(CVIB%)和后间隔基底段收缩期峰值应变率SR峰值,以及血清抗心肌肌钙蛋白I自身抗体(cTnIAAb)、可溶性信号素4D(sSema4D)和miR-34a-5p水平。结果:观察组总有效率高于对照组(P<0.05)。治疗后,观察组KCCQ评分较对照组高(P<0.05); 两组SR峰值、IBS%、CVIB%与治疗前比较有统计学差异,且观察组与对照组比较有统计学差异(均P<0.05); 两组患者血清cTnIAAb、sSema4D、miR-34a-5p水平较治疗前降低,观察组低于对照组(均P<0.05),且与超声检测结果存在一定相关性。结论:沙库巴曲缬沙坦钠治疗可有效改善蒽环类药物所致心肌损害患者的心功能,其内在机制可能与降低血清cTnIAAb和sSema4D、抑制miR-34a-5p表达、预防左心室重构相关。
Abstract:
Objective:To investigate the clinical efficacy of sacubitril valsartan sodium in the treatment of myocardial damage induced by anthracycline.Methods:70 patients with myocardial damage after treatment with azithromycin chemotherapy were randomly divided into observation group and control group,35 cases in each group.The control group received routine treatment such as correcting electrolyte disorder and removing inducement.On the basis of the control group,the observation group was given oral administration of sacubitril valsartan sodium for 12 weeks.The total effective rate,KCCQ score,LVEF,LVEDD,IBS%,CVIB% and SR peak of posterior septal basal,as well as serum levels of cTnIAAb,sSema4D and miR-34a-5p before and after treatment were compared between the two groups.Results:The total effective rate of the observation group was higher than that of the control group(P<0.05).After treatment,the KCCQ score of the observation group was higher than that of the control group(P<0.05); the SR peak,IBS% and CVIB% of the two groups were statistically different from those before treatment,and there were statistical differences between the two groups(all P<0.05); the levels of serum cTnIAAb,sSema4D and miR-34a-5p of the two groups were lower than those before treatment,and the observation group was lower than the control group(all P<0.05),and there was a certain degree of correlation with the results of ultrasound detection.Conclusion:Sacubitril valsartan sodium can effectively improve the cardiac function of patients with myocardial damage induced by anthracycline,and its internal mechanism may be related to reducing serum cTnIAAb and sSema4D,inhibiting the expression of miR-34a-5p,and preventing left ventricular remodeling.

参考文献/References:

[1] Ferraro MP,Gimeno-Vazquez E,Subirana I,et al.Anthracycline-induced cardiotoxicity in diffuse large B-cell lymphoma:NT-proBNP and cardiovascular score for risk stratification[J].Eur J Haematol,2019,102(6):509-515.
[2] 金爱萍,李 蔚,李 冰,等.AMP激活蛋白激酶对慢性心力衰竭进展影响的实验研究[J].陕西医学杂志,2021,50(1):3-6.
[3] Wojciechowska C,Romuk E,Nowalany-Kozielska E,et al.Serum galectin-3 and ST2 as predictors of unfavorable outcome in stable dilated cardiomyopathy patients[J].Hellenic J Cardiol,2017,58(5):350-359.
[4] 倪凤扬,姬新才,吴可君,等.慢性心力衰竭患者血清胱抑素C水平与抑郁障碍相关性分析[J].陕西医学杂志,2019,48(4):424-426,431.
[5] Yandrapalli S,Andries G,Biswas M,et al.Profile of sacubitril/valsartan in the treatment of heart failure:Patient selection and perspectives[J].Vasc Health Risk Manag,2017,5(13):369-382.
[6] 潘春奇,菅 颖,倪 斌,等.沙库巴曲缬沙坦对射血分数降低的缺血性心肌病患者心肌损伤和炎症因子的影响[J].中华全科医学,2020,18(11):1848-1850,1945.
[7] 王 毅,杨 征.托伐普坦和沙库巴曲缬沙坦钠片对慢性心力衰竭患者心功能及血清钠水平的影响研究[J].陕西医学杂志,2019,48(4):470-472.
[8] 中国临床肿瘤学会,中华医学会血液学分会.蒽环类药物心脏毒性防治指南(2013年版)[J].临床肿瘤学杂志,2013,18(10):925-934.
[9] Pecoraro M,Rodríguez-Sinovas A,Marzocco S,et al.Cardiotoxic effects of short-term doxorubicin administration:Involvement of connexin 43 in calcium impairment[J].Int J Mol Sci,2017,18(10):2121.
[10] Kavazis AN,Morton AB,Hall SE,et al.Effects of doxorubicin on cardiac muscle subsarcolemmal and intermyofbrillar mitochondria[J].Mitochondrion,2017,34(2):9-19.
[11] Yoon JH,Kim HJ,Lee EJ,et al.Early left ventricular dysfunction in children after hematopoietic stem cell transplantation for acute leukemia:A case control study using speckle tracking echocardiography[J].Korean Cric J,2015,45(1):51-58.
[12] Wu ZG,Li JG.Progress on the evaluation of cardiac toxicity of the anthracycline chemotherapy by echocardiography[J].Medical Recapitulate,2015,8:1452-1454.
[13] Stroikova V,Fischer A,Bockstahler M,et al.Adiponectin deficiency has no effect in murine autoimmune myocarditis[J].Cytokine,2019,9(116):139-149.
[14] Maleki KT,Cornillet M,Björkström NK.Soluble SEMA4D/CD100:A novel immunoregulator in infectious and inflammatory diseases[J].Clin Immunol,2016,163(9):52-59.
[15] Gong H,Lyu X,Li S,et al.SSema4D levels are increased in coronary heart disease and associated with the extent of coronary artery stenosis[J].Life Sci,2019,9(15):329-335.
[16] 唐俊燕,杨国杰,李栋博,等.血清可溶性Sema4D水平与扩张型心肌病心室重构的相关性研究[J].中国循环杂志,2017,32(1):63-66.
[17] Lu Q,Dong N,Wang Q,et al.Correction:Increased levels of plasma soluble Sema4D in patients with heart failure[J].PLoS One,2019,14(3):e0214894.
[18] Zhu JN,Fu YH,Hu ZQ,et al.Activation of miR-34a-5p/Sirt1/p66shc pathway contributes to doxorubicin-induced cardiotoxicity[J].Sci Rep,2017,7(1):11879.
[19] Yin Z,Zhao Y,Li H,et al.MiR-320a mediates doxorubicin-inducedcardiotoxicity by targeting VEGF signal pathway[J].Aging(Albany NY),2016,8(1):192-207.
[20] Boon RA,Jae N,Holdt L,et al.Long noncoding RNAs:From clinical genetics to therapeutic targets?[J].J Am Coll Cardiol,2016,67(10):1214-1226.

备注/Memo

备注/Memo:
基金项目:陕西省科技计划项目(XA2020-YXYJ-0161)
更新日期/Last Update: 2021-06-07